These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2813332)

  • 21. Ablation of phosphoinositide 3-kinase-gamma reduces the severity of acute pancreatitis.
    Lupia E; Goffi A; De Giuli P; Azzolino O; Bosco O; Patrucco E; Vivaldo MC; Ricca M; Wymann MP; Hirsch E; Montrucchio G; Emanuelli G
    Am J Pathol; 2004 Dec; 165(6):2003-11. PubMed ID: 15579443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Asperlicin: a unique nonpeptide cholecystokinin antagonist.
    Zucker KA; Adrian TE; Zdon MJ; Ballantyne GH; Modlin IM
    Surgery; 1987 Aug; 102(2):163-70. PubMed ID: 2441481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of peptide YY on CCK/CCK antagonist interactions in cerulein-induced pancreatic injury.
    Tito JM; Rudnicki M; Robinson DC; Guiney WB; Adrian TE; Gold MS
    Ann N Y Acad Sci; 1995 May; 757():410-2. PubMed ID: 7541974
    [No Abstract]   [Full Text] [Related]  

  • 24. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.
    Singh L; Lewis AS; Field MJ; Hughes J; Woodruff GN
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1130-3. PubMed ID: 1996314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asperlicin, a nonpeptidal cholecystokinin receptor antagonist, attenuates sodium taurocholate-induced acute pancreatitis in rats.
    Wisner JR; Renner IG
    Pancreas; 1988; 3(2):174-9. PubMed ID: 2453874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective effect of CR 1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and mice.
    Makovec F; Bani M; Cereda R; Chistè R; Revel L; Rovati LC; Setnikar I; Rovati LA
    Peptides; 1986; 7(6):1159-64. PubMed ID: 3104890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of antioxidants and free radical scavengers in three different models of acute pancreatitis.
    Niederau C; Niederau M; Borchard F; Ude K; Lüthen R; Strohmeyer G; Ferrell LD; Grendell JH
    Pancreas; 1992; 7(4):486-96. PubMed ID: 1641391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential role of cholecystokinin in the development of acute pancreatitis.
    Beglinger C
    Digestion; 1999; 60 Suppl 1():61-3. PubMed ID: 10026434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of somatostatin analogue and cholecystokinin receptor antagonist on bile-induced acute canine pancreatitis.
    Ko TC; Bertram MF; Prinz RA; Castelli M; Djuricin G; Jacobs HK
    Am Surg; 1992 Apr; 58(4):213-9. PubMed ID: 1375011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze.
    Vasar E; Lang A; Harro J; Bourin M; Bradwejn J
    Neuropharmacology; 1994 Jun; 33(6):729-35. PubMed ID: 7936110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 'Anxiolytic' effect of CCK-antagonists on plus-maze behavior in mice.
    Rataud J; Darche F; Piot O; Stutzmann JM; Böhme GA; Blanchard JC
    Brain Res; 1991 May; 548(1-2):315-7. PubMed ID: 1868342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholecystokinin antagonist L364,718 induces alterations in acinar cells that prevent improvement of acute pancreatitis induced by obstruction.
    De Dios I; Uruñuela A; Orfao A; Manso MA
    Dig Dis Sci; 2002 Aug; 47(8):1800-9. PubMed ID: 12184533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antagonism of central and peripheral anorectic effects of caerulein by L-364,718.
    Leighton GE; Griesbacher T; Hill RG; Hughes J
    Eur J Pharmacol; 1989 Feb; 161(2-3):255-8. PubMed ID: 2721558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholecystokinin blockade triggers earlier and enhanced intra-acinar oxygen free radical generation in acute pancreatitis induced by pancreatic duct obstruction in rats.
    Uruñuela A; Manso MA; de la Mano AM; de Dios I
    Clin Sci (Lond); 2003 Aug; 105(2):203-12. PubMed ID: 12713440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amelioration of cholinergic-induced pancreatitis with a selective cholecystokinin receptor antagonist.
    Bilchik AJ; Zucker KA; Adrian TE; Modlin IM
    Arch Surg; 1990 Dec; 125(12):1546-9. PubMed ID: 2244806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of CCK-A receptors induces elevation of plasma corticosterone in rats.
    Katsuura G; Ibii N; Matsushita A
    Peptides; 1992; 13(1):203-5. PubMed ID: 1620654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of a new CCK antagonist, L364,718: in vitro and in vivo studies.
    Louie DS; Liang JP; Owyang C
    Am J Physiol; 1988 Sep; 255(3 Pt 1):G261-6. PubMed ID: 2458681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CCK-antagonist L-364,718: influence on rat pancreatic growth induced by caerulein and bombesin-like peptides.
    Schmidt WE; Choudhury AR; Siegel EG; Löser C; Conlon JM; Fölsch UR; Creutzfeldt W
    Regul Pept; 1989 Jan; 24(1):67-79. PubMed ID: 2544930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for a physiological role for CCK in the regulation of food intake in mice.
    Silver AJ; Flood JF; Song AM; Morley JE
    Am J Physiol; 1989 Mar; 256(3 Pt 2):R646-52. PubMed ID: 2923253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholecystokinin type A and type B receptor antagonists produce opposing effects on cholecystokinin-stimulated beta-endorphin secretion from the rat pituitary.
    Millington WR; Mueller GP; Lavigne GJ
    J Pharmacol Exp Ther; 1992 May; 261(2):454-61. PubMed ID: 1578360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.